Belgian consensus on pneumococcal vaccine

Acta Clinica Belgica

Volumn 51, Issue 5, 1996, Pages 350-356

  Peetermans, W ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

BELGIUM; HUMAN; INFECTION CONTROL; PNEUMONIA; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

AGED; BACTERIAL VACCINES; BELGIUM; FEMALE; HEALTH POLICY; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0029800021     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Vandepitte J. Who is afraid of the pneumococcus? Acta Clin Belg. 1993; 48: 143-7.
2. Immunization Practices Advisory Committee. Pneumococcal polysaccharide vaccine.MMWR. 1989; 38: 64-76.
3. Verhaegen J, Glupczynski Y, Verbist L et al. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis. 1995; 20: 1339-45.
4. Alonso De Velasco E, Verheul AFM, Verhoef J, Snippe H. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev. 1995; 59: 591-603.
5. Bruyn GAW, Zegers BJM, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis. 1992; 14: 251-62.
6. Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis. 1993; 17: 66-73.
7. Hirshman JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med. 1994; 154: 373-7.
8. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. Arch Intern Med. 1994; 154: 2666-77.
9. Bruyn GAW, van Furth R. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis. 1991; 10: 897-910.
10. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991; 325: 1453-60.
11. Butler JC, Breiman RF, Campbell JF et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993; 270: 1826-31.
12. Farr BM, Johnston BL, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995; 155: 2336-40.
13. Fedson D, Henrichsen J, Mäkelä PH, Austrian R. WHO recommendations on pneumococcal vaccination. Infection. 1989; 17: 437-41
14. Steven N, Wright P. Pneumococcal immunisation and the healthy elderly. Lancet. 1992; 340: 1036-37.
15. Gable CB, Holzer SS, Engelhart L et al. Pneumococcal vaccine. Efficacy and associated cost savings. JAMA. 1990; 264: 2910-15.
16. Read RC, Finch RG. Prophylaxis after splenectomy. J Antimicrob Chemother. 1994; 33: 4-6.
17. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994; 8: 469-76.
18. Mascart-Lemone, Gerard M, Libin M et al. Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. J Infect Dis. 1995; 172: 1253-60.